1-3 of 3
Catherine Hildyard, MRCP, BA
Close
Sort by
Journal Articles

A Phase II Study to Determine the Safety and Efficacy of the Dual m-TORC Inhibitor AZD2014 and to Investigate Additional Toxicities in Combination with Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Toby A. Eyre, MBBChir, MRCP, Catherine Hildyard, MRCP, BA, Anesh Panchal, BSc, MSc, Aimee E Houlton, BSc, MSc, Louise Hopkins, BSc, MRes, Angela Hamblin, MD PhD, Kim Linton, MBChB PhD, Andrew Pettitt, FRCPath, PhD, Simon Rule, MD, Kate Cwynarski, PhD MD, Sally Barrington, MBBS, MSc, FRCP, FRCR, MD, David Wrench, MA, MBBChir, FRCPath, PhD, Andrew Davies, PhD, Graham Collins, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5210.
https://doi.org/10.1182/blood.V130.Suppl_1.5210.5210
Published: 2017
Journal Articles

18 f-FDG PET-CT Assessment of Responses to Salvage Therapy and Autologous Stem Cell Transplant (ASCT) in Relapsed/Refractory Classical Hodgkin Lymphoma (cHL)

Maciej Tatarczuch, BMBS, FRACP, FRCPA, Catherine Hildyard, MRCP, BA, Manil Subesinghe, MBBS, MRCP, FRCR., Toby A. Eyre, MBBChir, MRCP, Graham Collins, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5181.
https://doi.org/10.1182/blood.V130.Suppl_1.5181.5181
Published: 2017
Journal Articles

Interim Results from a Phase 1 Study of ADCT-301 (Camidanlumab Tesirine) Show Promising Activity of a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate in Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma

Steven M. Horwitz, MD, Mehdi Hamadani, MD, Michelle A. Fanale, MD, Jay Feingold, MD PhD, Alexander I Spira, MD, Paul A Fields, MD PhD, Tobias Menne, MD PhD, Anand Karnad, MD, Alison J. Moskowitz, MD, Catherine Hildyard, MRCP, BA, Shui He, PhD, Joseph Boni, PhD, Graham Collins, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1510.
https://doi.org/10.1182/blood.V130.Suppl_1.1510.1510
Published: 2017